CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Activa PC+S Neurostimulatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03180515
NCT03180515N/ACompleted
CompareCT.gov

Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation

Stanford University·interventional·Posted Jun 8, 2017·Updated Nov 21, 2019

In Brief

A clinical study evaluating Activa PC+S Neurostimulator for Parkinson Disease. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Continuous deep brain stimulation (cDBS) is an established therapy for the major motor signs in Parkinson's disease, however some patients find that it does not adequately treat their freezing of gait (FOG). Currently, cDBS is limited to "open-loop" stimulation,without real-time adjustment to the patient's state of activity, fluctuations and types of motor symptoms, medication dosages, or neural markers of the disease. The purpose of this study is to determine if an adaptive DBS system,responding to patient specific, clinically relevant neural or kinematic feedback related to FOG, is more effective than continuous DBS on the motor Unified Parkinson's Disease Rating Scale (UPDRS III) and gait measures of PD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 8, 2017
Enrollment StartMay 15, 2017
Primary CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.1 years ago

Interventions

Activa PC+S Neurostimulatordevice

Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.